Is a complete CBIO research report available?

No complete published report is available for Crescent Biopharma, Inc. (CBIO) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Crescent Biopharma, Inc. (CBIO)

NASDAQ: CBIO · USD

$15.0

+0.25 (+1.7%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first CBIO analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	620.7M
Revenue (ttm)	11.9M
Net income (ttm)	-162.1M
EPS (ttm)	-$8.05
Shares out	41.3M
Volume	283,733
Price target	$31.0	+106.4%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 11.9M
Net income (ttm): -162.1M
EPS (ttm): -$8.05
Market cap: 620.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All CBIO indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001124105
Company name	Crescent Biopharma, Inc.
Country	United States
Country code	US
Cusip	G2545C104
Employees	55
Employees Change	11%
Employees Change Percent	25
Enterprise value	$433.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	KYG2545C1042
Last refreshed	2026-07-31
Market cap	$620.7M
Market cap category	Small-Cap
Price	$15.02
Price currency	USD
Rev Per Employee	216,054.55x
Sector	Healthcare
Sector PE	45.56
Sector PE Fwd	24.38
Sic	2834
Symbol	CBIO
Website	https://crescentbiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-26.11%
EV Sales Forward	404.2x
EV/Sales	36.44x
FCF yield	-11.39%
P/B ratio	2.78x
P/S ratio	52.23x
PS Forward	579.31x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$11.9M
Net Income	$-162.1M
Net Income Growth Years	0%
Pretax Margin	-1,347.11%
Profit Per Employee	$-2.9M
ROCE	-91.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	22.13%
EPS Growth Quarters	4
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$199.1M
Cash	$189.2M
Current Assets	$195.6M
Current Liabilities	$14.2M
Debt	$1.5M
Debt Equity	$0.01
Equity	$183.8M
Interest Coverage	-157
Liabilities	$15.3M
Long Term Assets	$3.6M
Long Term Liabilities	$1.1M
Net Cash	$187.6M
Net Cash By Market Cap	$30.23
Net Debt Equity	$-1.02
Tangible Book Value	$179.8M
Tangible Book Value Per Share	$5.41

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	13.78
Net Working Capital	$-7.3M
Quick ratio	13.33
Working Capital	$181.4M
Working Capital Turnover	$0.13

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	22.11%
200-day SMA	14.86
50-day SMA	17.55
50-day SMA vs 200-day SMA	50over200
All Time High	27.41
All Time High Change	-45.2%
All Time High Date	2026-04-22
All Time Low	8.72
All Time Low Change	72.25%
All Time Low Date	2026-02-09
ATR	1.44
Beta1y	1.55
Beta2y	1.58
Ch YTD	26.64
High	15.44
High52	27.41
High52 Date	2026-04-22
High52ch	-45.2%
Low	14.36
Low52	8.72
Low52 Date	2026-02-09
Low52ch	72.25%
Ma50ch	-14.42%
Price vs 200-day SMA	1.1%
RSI	41.59
RSI Monthly	0
RSI Weekly	46.93
Sharpe ratio	0.59x
Sortino ratio	1.02
Tr YTD	26.64
Tr1m	-16.56%
Tr1w	-11.8%
Tr3m	-28.27%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	7
Analyst Price Target Top	$31
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.67
Earnings Revenue Estimate	357,140x
Operating Income	$-163.1M
Operating margin	-1,372.9
Price target	$31
Price Target Change	$106
Price Target Change Top	$106

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	23,020,563%
Float Percent	55.71%
Shares Insiders	4.96%
Shares Institutions	45.08%
Shares Out	41,323,850
Shares Qo Q	44.35%
Short Float	16.26%
Short Ratio	8.37
Short Shares	9.06

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-86.9M
Adjusted OCF	-85,802,000
Average Volume	409,985.15x
Bv Per Share	5.41
CAPEX	$-1.1M
Ch1m	-16.56
Ch1w	-11.8
Ch1y	22.11
Ch3m	-28.27
Ch6m	48.05
Change	1.69%
Change From Open	2.46
Close	14.77
Days Gap	-0.74
Depreciation Amortization	148,000
Dollar Volume	4,261,669.7
Earnings Date	2026-07-30
Earnings Time	bmo
EBIT	$-168.5M
EBITDA	$-168.3M
EPS	$-8.05
F Score	1
FCF	$-70.7M
FCF EV Yield	-16.32x
FCF Per Share	$-1.71
Financing CF	317,525,000
Fiscal Year End	December
Founded	2,003
Income Tax	$2M
Investing CF	-81,066,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-13
Ma150	15.48
Ma150ch	-3%
Ma20	16.13
Ma20ch	-6.86%
Net CF	166,841,000
Next Earnings Date	2026-11-05
Open	14.66
Optionable	No
Position In Range	61.11
Post Close	15.02
Postmarket Change Percent	3.2
Postmarket Price	$15.5
Ppne	2,301,000
Price Date	2026-07-30
Ptbv Ratio	3.45
Relative Volume	0.69x
Revenue	11,883,000x
SBC By Revenue	136.19x
Share Based Comp	16,184,000
Tax By Revenue	16.83x
Tr6m	48.05%
Us State	Massachusetts
Volume	283,733
Z Score	7.59

Crescent Biopharma, Inc. (CBIO)

Coverage state: Market snapshot only — no published research

Generate the first CBIO analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · CBIO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CBIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on CBIO

Frequently asked questions